BELLUS Health

93 articles with BELLUS Health

• BELLUS Health Announces Pricing of US$35 Million Public Offering in Canada and the United States

  10/20/2020

  In connection with its previously announced public offering of common shares in Canada and the United States, BELLUS Health Inc. announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies and Evercore ISI as joint book-running managers, and LifeSci Capital as co-manager, relating to the public offering of 15,555,556 common shares.

• BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough

  9/8/2020

  Double-blind, 4-week placebo controlled, parallel arm trial will evaluate the efficacy and safety of 3 doses of BLU-5937 in 280 patients with refractory chronic cough

• BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences - Sep 03, 2020

  9/3/2020

  BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming virtual healthcare investor conferences.

• BELLUS Health Reports Second Quarter 2020 Financial Results and Business Highlights

  8/13/2020

  Phase 2b Trial Design for BLU-5937 in Refractory Chronic Cough to be Announced in Q3 2020

• BELLUS Health Announces Topline Results from its Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

  7/6/2020

  Primary endpoint of placebo-adjusted reduction in awake cough frequency did not reach statistical significance

• BELLUS Health to Participate in Fireside Chat at the Jefferies 2020 Virtual Healthcare Conference

  5/28/2020

  BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.

• BELLUS Health Reports First Quarter 2020 Financial Results and Business Highlights, and Provides Updates on BLU-5937

  5/14/2020

  BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, reported its financial and operating results for the first quarter ended March 31, 2020.

• BELLUS Health Convenes Virtual KOL Meeting to Discuss the State of Chronic Cough Treatment and the BLU-5937 Program

  5/13/2020

  BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a virtual Key Opinion Leader (“KOL”) meeting to discuss the chronic cough landscape on Wednesday, May 27, 2020 at 9:00 a.m. EDT. The event will featur

• BELLUS Health to Present at the BofA Securities Virtual Health Care Conference

  5/6/2020

  BELLUS Health Inc. announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Tuesday, May 12, 2020 at the BofA Securities Virtual Health Care Conference.

• BELLUS Health Announces Change to Annual and Special Shareholder Meeting Format

  5/5/2020

  Meeting to be held by webcast as a result of public health measures in response to the COVID-19 pandemic

• BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough

  4/6/2020

  BELLUS Health Inc. announced that it has completed patient dosing in its Phase 2 RELIEF clinical trial of BLU-5937 for the treatment of refractory chronic cough, with 52 patients completing treatment.

• BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations

  3/25/2020

  BELLUS now owns 100% of BLU-5937 and related P2X3 antagonist intellectual property with no future payments due

• BELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations

  3/23/2020

  BELLUS to own 100% of BLU-5937 and related P2X3 antagonists intellectual property with no future payments due -

• BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

  3/19/2020

  BELLUS Health Inc. announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients with refractory chronic cough.

• BELLUS Health Reports Full Year 2019 Financial Results and Business Highlights on BLU-5937

  2/27/2020

  BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ended December 31, 2019. “The Company closed 2019 on a strong, positive trajectory, and we look at the past year as one of

• BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019

  11/14/2019

  BELLUS Health Inc. reported its financial and operating results for the third quarter ended September 30, 2019.

• BELLUS Health to Present at Jefferies Global Healthcare Conference in London

  11/13/2019

  BELLUS Health Inc. announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.

• BELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common Shares

  9/17/2019

  Company has raised total gross proceeds of approximately US$79.37 million from the Offering, before deducting the underwriting commissions and any expenses related to the Offering.

• BELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United States

  9/9/2019

  The Company has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,478,873 common shares from the Company on the same terms and conditions.

• BELLUS Health Announces Pricing of US$70 Million Public Offering in Canada and the United States

  9/5/2019

  In connection with its previously announced public offering of common shares in Canada and the United States, BELLUS Health Inc., announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Cowen and Guggenheim Securities, as joint book-running managers, Baird, as lead manager, and Bloom Burton Securities, as co-manager